---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000062"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:54:38.270928+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Praxis Precision reports sustained seizure reduction with relutrigine, announces Phase 3 trial design

## Summary
- Updated EMBOLD open-label data (n=12) show sustained seizure reduction and increased seizure-free periods through 11 months of relutrigine treatment in SCN2A/SCN8A DEEs.
- Announced EMERALD Phase 3 trial design: randomized, placebo-controlled, 160 patients aged 2–65 years, 16-week treatment period.
- Plans to nominate development candidate for PRAX-100, an antisense oligonucleotide targeting SCN2A loss-of-function in autism, in mid-2025.
- Corporate presentation furnished as Exhibit 99.1 includes program updates provided at May 2, 2025 investor event.

## SEC filing metadata
- accession: 0001689548-25-000062
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/0001689548-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/prax-20250502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000062
- JSON: https://secwatch.observer/filing/0001689548-25-000062.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.